UNASSIGNED: We retrospectively enrolled 1,763 BC patients treated in a single institution from 2017 to 2018. TILs are regarded as continuous variables and are divided into low TILs (≤10%) and high TILs (>10%) for statistical analysis. Univariate and multivariable Cox proportional hazards regression models were used to test the associations between TILs and disease-free survival (DFS) with adjustment for clinicopathologic characteristics.
UNASSIGNED: High TIL levels (>10%) were associated with tumor size (>2 cm, p = 0.042), age at diagnosis (p = 0.005), Ki-67 index (>25%; p <0.001), HR (hormone receptor) status (positive, p <0.001), advanced pathological stage (p = 0.043), subtype (p <0.001), and HER2 status (p <0.001). The Kaplan-Meier analysis indicated that no significant difference in DFS (p = 0.83) could be found between HER2-positive, HER2-low-positive, and HER2-0 BC. The DFS of HER2-low-positive BC and HER2-nonamplified BC with high levels of TILs was statistically better than that of patients with low levels of TILs (p = 0.015; p = 0.047). In HER2-low-positive BC patients with high TIL levels (>10%), DFS was significantly improved in both the univariate (HR = 0.44, 95% CI 0.22-0.87, P = 0.018) and multivariate (HR = 0.47, 95% CI 0.23-0.95, P = 0.035) Cox models. For further subgroup analysis, HR (+)/HER2-low-positive BC with high TIL (>10%) levels was associated with improved DFS in both the univariate (HR = 0.41, 95% CI 0.19-0.90, P = 0.025) and multivariate (HR = 0.42, 95% CI 0.19-0.93, P = 0.032) Cox models. The HR (-)/HER2-0 BC with high TIL (>10%) level was not statistically significant in the univariate Cox model, but it was statistically significant in the multivariate (HR = 0.16, 95% CI 0.28-0.96, P = 0.045) Cox model.
UNASSIGNED: Among early-stage BC, no significant survival difference could be found between the HER2-positive, HER2-low-positive, and HER2-0 cohorts. High levels of TILs were significantly associated with improved DFS in HER2-low-positive patients, especially in the HR (+)/HER2-low-positive subtype.
■我们回顾性地纳入了2017年至2018年在单一机构接受治疗的1,763例BC患者。TIL被视为连续变量,分为低TIL(≤10%)和高TIL(>10%)进行统计分析。使用单变量和多变量Cox比例风险回归模型来测试TILs与无病生存期(DFS)之间的关联,并调整临床病理特征。
■高TIL水平(>10%)与肿瘤大小(>2厘米,p=0.042),诊断年龄(p=0.005),Ki-67指数(>25%;p<0.001),HR(激素受体)状态(阳性,p<0.001),晚期病理阶段(p=0.043),亚型(p<0.001),和HER2状态(p<0.001)。Kaplan-Meier分析表明,在HER2阳性之间没有发现DFS的显着差异(p=0.83)。HER2-低阳性,和HER2-0BC。具有高水平TIL的HER2低阳性BC和HER2非扩增BC的DFS在统计学上优于具有低水平TIL的患者(p=0.015;p=0.047)。在具有高TIL水平(>10%)的HER2低阳性BC患者中,单变量(HR=0.44,95%CI0.22-0.87,P=0.018)和多变量(HR=0.47,95%CI0.23-0.95,P=0.035)Cox模型的DFS均显着改善。对于进一步的亚组分析,在单变量(HR=0.41,95%CI0.19-0.90,P=0.025)和多变量(HR=0.42,95%CI0.19-0.93,P=0.032)Cox模型中,高TIL(>10%)水平的HR()/HER2低阳性BC与DFS改善相关。高TIL(>10%)水平的HR(-)/HER2-0BC在单变量Cox模型中没有统计学意义,但在多变量(HR=0.16,95%CI0.28-0.96,P=0.045)Cox模型中有统计学意义.
■在早期BC中,在HER2阳性患者之间没有发现显著的生存差异,HER2-低阳性,和HER2-0队列。高水平的TIL与HER2低阳性患者的DFS改善显著相关,特别是在HR(+)/HER2低阳性亚型中。